<DOC>
	<DOCNO>NCT02387580</DOCNO>
	<brief_summary>This single-centre , 2-part , randomised , single-dose parallel group study healthy male subject female subject non-childbearing potential .</brief_summary>
	<brief_title>Bioavailability Study Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate ( PQP ) Tablets</brief_title>
	<detailed_description>Parts 1 2 randomise 8 subject receive regimen : Part 1 : - Regimen A : Reference : 800 mg OZ439 + α-Tocopherol polyethylene glycol 1000 succinate ( TPGS ) granule ( oral suspension 240 mL volume 100 mL rinse volume ) 960 mg ( 3 × 320 mg ) PQP tablets - Regimen B : Prototype 1 : 800 mg OZ439 granule ( oral suspension 60 mL volume 50 mL rinse volume ) 960 mg ( 3 × 320 mg ) PQP tablets - Regimen C : Prototype 3 : 800 mg OZ439 granule ( oral suspension 60 mL volume 50 mL rinse volume ) 960 mg ( 3 × 320 mg ) PQP tablets There interim decision Part 1 determine formulation prototypes oral suspension volume administer Part 2 . Part 2 - Regimen D : Reference : 800 mg OZ439 + TPGS granule ( oral suspension 240 mL volume 100 mL rinse volume ) 960 mg ( 3 × 320 mg ) PQP tablets - Regimen E : Prototype 1 3 : 800 mg OZ439 granule ( oral suspension rinse volume determine ) 960 mg ( 3 × 320 mg ) PQP tablets - Regimen F : Prototype 1 3 : 800 mg OZ439 granule ( oral suspension rinse volume determine ) 960 mg ( 3 × 320 mg ) PQP tablet</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Healthy male , healthy female nonchildbearing potential ie surgically sterilise postmenopausal Body mass index 18.0 30.0 kg/m2 inclusive . Total body weight &gt; 50 kg screening . Must agree use adequate method contraception . Normal laboratory test judge Investigator . Must QTcF ≤450 m , QTcB ≤450 m male subject , QTcF ≤470 m , QTcB ≤470 m female subject PR interval ≤200 m screen predose ECG measurement . Male subject currently pregnant partner partner plan pregnant . Evidence history clinically significant disease , current infection.3 . Clinically relevant abnormality ECG . Family history sudden death congenital prolongation QTc interval know congenital prolongation QTc interval clinical condition know prolong QTc interval . History symptomatic cardiac arrhythmia clinically relevant bradycardia , heart rate ≤39 bpm . Electrolyte disturbance , particularly hypokalaemia , hypocalcaemia hypomagnesaemia . History drug alcohol abuse past 2 year prior screen . Receipt investigational drug participation another clinical research study within 90 day prior drug administration . Use prescription nonprescription medication , vitamin , herbal supplement dietary supplement , include protein supplement , within 14 day prior first dose study drug . Positive hepatitis B surface antigen , hepatitis C virus antibody human immunodeficiency virus result . Clinically significant abnormal biochemistry , haematology urinalysis . Positive urine drug screen result . History intolerance hypersensitivity PQP 4aminoquinoline , ascertain presumptive hypersensitivity active principle and/or formulation ingredient ; history anaphylaxis drug allergic reaction general , investigator considers may affect outcome study . Presence history allergy require treatment ; hayfever allow unless active . Donation loss &gt; 400 mL blood within 90 day prior drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Formulation</keyword>
</DOC>